Vaxcyte begins first human trial of Group A strep vaccine candidate

June 2, 2026 4:05 PM

Vaxcyte Inc. (NASDAQ: PCVX) dosed the first participant in a Phase 1 study evaluating VAX-A1, its investigational vaccine candidate designed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found